Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073954 | 0.88 | SIGMAR1 (0.54) | SIGMAR1HTTL3MBTL1CNR2 | |
| SCHEMBL3043755 | 0.87 | SIGMAR1 (0.54) | SIGMAR1HTTL3MBTL1ADRA2AADRA2B | |
| SCHEMBL14681114 | 0.84 | SIGMAR1 (0.59) | SIGMAR1ADRA2AADRA2BADRA2CHRH1 | |
| SCHEMBL7712083 | 0.82 | SIGMAR1 (0.63) | SIGMAR1CNR2 | |
| SCHEMBL28909421 | 0.81 | SIGMAR1 (0.54) | SIGMAR1ADRA2AADRA2BADRA2CHRH1 | |
| SCHEMBL2403333 | 0.79 | SIGMAR1 (0.50) | SIGMAR1CNR2MAPT | |
| SCHEMBL2407440 | 0.79 | SIGMAR1 (0.50) | SIGMAR1HTTL3MBTL1MAPT | |
| SCHEMBL12124672 | 0.79 | SIGMAR1 (0.66) | SIGMAR1ADRA2AADRA2BADRA2CHRH1 | |
| SCHEMBL17288108 | 0.77 | SIGMAR1 (0.51) | SIGMAR1HTTADRA2AADRA2BADRA2C | |
| SCHEMBL7716707 | 0.77 | SIGMAR1 (0.51) | SIGMAR1L3MBTL1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | SIGMAR1 229/4885HTT 3449/4885L3MBTL1 4029/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | SIGMAR1 229/4885HTT 3449/4885L3MBTL1 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.